Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer:...

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths.
• The epidermal growth factor receptor (EGFR) T790M mutation is a common resistance mechanism to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs).
• Third-generation EGFR-TKIs have been developed to target this specific mutation.

Purpose of the Study:

• To systematically review research advances on third-generation EGFR-TKIs.
• To compare pharmacokinetics, pharmacodynamics, and adverse events of osimertinib, almonertinib, and furmonertinib.
• To provide references for optimal clinical drug selection in NSCLC patients with EGFR T790M mutations.

Main Methods:

• Systematic literature review of research advances.
• Comparative analysis of pharmacokinetic and pharmacodynamic profiles.
• Review of treatment-related adverse events and clinical outcomes.

Main Results:

• Osimertinib, almonertinib, and furmonertinib are approved third-generation EGFR-TKIs for NSCLC with EGFR T790M mutations.
• Significant differences exist in dosing schedules and the incidence of adverse events among these three drugs.
• Individualized selection based on drug profiles may maximize benefits.

Conclusions:

• Third-generation EGFR-TKIs represent a significant advancement in NSCLC treatment.
• Understanding the distinct characteristics of each TKI is crucial for effective patient management.
• Personalized therapeutic strategies are essential for optimizing outcomes in NSCLC patients harboring the EGFR T790M mutation.